Eisai Co. vs Alnylam Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Eisai Co., Ltd. (4523.JP)

Q3 202630 Jun – 25 Sep 2026

▲4

Eisai Q3: Leqembi at-home approvals and oncology wins drive growth

Leqembi at-home subcutaneous approval and launches The FDA approved at-home subcutaneous Leqembi/Iqlik, with launches in the US, plus approvals in China and Japan enabling at-home use. This expands patient access and convenience, potentially boosting sales.
This is a major new approval and launch that directly impacts Eisai's growth prospects.
Strong Leqembi sales and royalty growth Q2 Leqembi sales reached ¥29.3bn, with royalties up 43% excluding China stockpiling. This indicates robust demand and successful commercialization.
Sales and royalty figures are key financial metrics showing Leqembi's market performance.
Oncology pipeline advances UK validated taletrectinib, and the FDA approved WELIREG plus LENVIMA for advanced kidney cancer. These expand Eisai's oncology portfolio and revenue potential.
New approvals and validations in oncology represent additional growth drivers beyond Leqembi.
AI drug-discovery partnership with Nvidia Eisai joined Nvidia’s AI drug-discovery push, which could enhance future pipeline productivity and innovation.
This strategic move may improve long-term R&D efficiency and is a new development.

August 202629 Jul – 25 Sep 2026

▲5

Leqembi's Global Rollout Accelerates with New Approvals and Reimbursement

Leqembi Q2 Sales Show Strong Underlying Growth Leqembi sales hit 29.3 billion yen in Q2 2026, with royalty revenue up 43% excluding a one-time China stockpiling effect. This signals robust real demand, supporting Eisai's revenue and profit outlook.
Shows strong sales momentum, a key driver of Eisai's earnings and stock price.
FDA Approves Leqembi Autoinjector, Expanding US Access The FDA approved Leqembi Iqlik subcutaneous autoinjector for weekly initiation, with a US launch in August. This makes treatment easier and more convenient, likely boosting patient uptake and sales.
New approval expands market access and convenience, directly driving future sales.
Canada Recommends Public Reimbursement for Leqembi Canada's Drug Agency gave a final positive recommendation for public reimbursement of Leqembi. This paves the way for government-funded access, potentially increasing patient numbers and sales in Canada.
Reimbursement is crucial for uptake; this opens a new market for Eisai.
China and Japan Approve Subcutaneous Leqembi, Enabling At-Home Use China and Japan approved subcutaneous Leqembi, allowing at-home administration. This could significantly boost adoption by removing the need for hospital infusions, expanding the patient pool in two major markets.
Subcutaneous approval in key markets improves convenience and access, driving demand.
FDA Approves WELIREG Plus LENVIMA for Advanced Kidney Cancer The FDA approved the combination of WELIREG and Eisai's LENVIMA for advanced kidney cancer, based on a trial showing reduced progression risk. This adds a new revenue stream for Eisai's oncology portfolio.
New approval diversifies Eisai's revenue beyond Alzheimer's, supporting growth.

Latest29 Jul – 25 Sep 2026

▲5

Leqembi's Global Rollout Accelerates with New Approvals and Reimbursement

Leqembi Q2 Sales Show Strong Underlying Growth Leqembi sales hit 29.3 billion yen in Q2 2026, with royalty revenue up 43% excluding a one-time China stockpiling effect. This signals robust real demand, supporting Eisai's revenue and profit outlook.
Shows strong sales momentum, a key driver of Eisai's earnings and stock price.
FDA Approves Leqembi Autoinjector, Expanding US Access The FDA approved Leqembi Iqlik subcutaneous autoinjector for weekly initiation, with a US launch in August. This makes treatment easier and more convenient, likely boosting patient uptake and sales.
New approval expands market access and convenience, directly driving future sales.
Canada Recommends Public Reimbursement for Leqembi Canada's Drug Agency gave a final positive recommendation for public reimbursement of Leqembi. This paves the way for government-funded access, potentially increasing patient numbers and sales in Canada.
Reimbursement is crucial for uptake; this opens a new market for Eisai.
China and Japan Approve Subcutaneous Leqembi, Enabling At-Home Use China and Japan approved subcutaneous Leqembi, allowing at-home administration. This could significantly boost adoption by removing the need for hospital infusions, expanding the patient pool in two major markets.
Subcutaneous approval in key markets improves convenience and access, driving demand.
FDA Approves WELIREG Plus LENVIMA for Advanced Kidney Cancer The FDA approved the combination of WELIREG and Eisai's LENVIMA for advanced kidney cancer, based on a trial showing reduced progression risk. This adds a new revenue stream for Eisai's oncology portfolio.
New approval diversifies Eisai's revenue beyond Alzheimer's, supporting growth.

July 202630 Jun – 16 Jul 2026

▲4

FDA clears at-home Leqembi shot; real-world data and AI deal add momentum

FDA approves at-home Leqembi injection The FDA approved LEQEMBI IQLIK, a once-weekly under-the-skin injection, as a starting dose for early Alzheimer's. It is the first anti-amyloid therapy with at-home dosing from the start, launching in late August. Easier use could widen demand and lift 4523.JP.
This is the period's biggest new approval, directly expanding Leqembi's market and Eisai's revenue potential.
Real-world study backs Leqembi benefit A real-world LEADER study found 83% of early Alzheimer's patients on LEQEMBI stayed stable or improved over about 17 months. This independent evidence supports the drug's effectiveness, which can reassure doctors, patients and payers, supporting 4523.JP.
New real-world data strengthens the commercial case for Leqembi beyond clinical trials.
UK validates taletrectinib lung cancer filing Eisai's UK marketing application for taletrectinib in ROS1-positive lung cancer was validated by the MHRA, adding to an EU filing. Approval would expand Eisai's oncology sales in licensed territories, a smaller but real positive for 4523.JP.
New regulatory progress for a second Eisai drug diversifies growth beyond Alzheimer's.
Eisai joins Nvidia AI drug discovery push Eisai is deploying Nvidia's BioNeMo platform for AI-powered drug discovery, part of Nvidia's broad Japan AI partnerships. Faster, cheaper early research could improve Eisai's pipeline productivity over time, a modest but supportive signal for 4523.JP.
New AI partnership shows Eisai investing in research efficiency, a longer-term positive.

30 Jun – 16 Jul 2026

▲4

FDA clears at-home Leqembi shot; real-world data and AI deal add momentum

FDA approves at-home Leqembi injection The FDA approved LEQEMBI IQLIK, a once-weekly under-the-skin injection, as a starting dose for early Alzheimer's. It is the first anti-amyloid therapy with at-home dosing from the start, launching in late August. Easier use could widen demand and lift 4523.JP.
This is the period's biggest new approval, directly expanding Leqembi's market and Eisai's revenue potential.
Real-world study backs Leqembi benefit A real-world LEADER study found 83% of early Alzheimer's patients on LEQEMBI stayed stable or improved over about 17 months. This independent evidence supports the drug's effectiveness, which can reassure doctors, patients and payers, supporting 4523.JP.
New real-world data strengthens the commercial case for Leqembi beyond clinical trials.
UK validates taletrectinib lung cancer filing Eisai's UK marketing application for taletrectinib in ROS1-positive lung cancer was validated by the MHRA, adding to an EU filing. Approval would expand Eisai's oncology sales in licensed territories, a smaller but real positive for 4523.JP.
New regulatory progress for a second Eisai drug diversifies growth beyond Alzheimer's.
Eisai joins Nvidia AI drug discovery push Eisai is deploying Nvidia's BioNeMo platform for AI-powered drug discovery, part of Nvidia's broad Japan AI partnerships. Faster, cheaper early research could improve Eisai's pipeline productivity over time, a modest but supportive signal for 4523.JP.
New AI partnership shows Eisai investing in research efficiency, a longer-term positive.

Alnylam Pharmaceuticals Inc (ALNY)

Q3 20269 Jul – 31 Jul 2026

▲2▼2

Alnylam's TTR Guidance Cut Triggers 29% Plunge Despite Record Quarter

TTR Guidance Cut Sends Shares Down 29% Alnylam lowered its 2026 TTR revenue guidance to $4.2–4.5 billion from $4.4–4.7 billion, citing slower second-line demand for Amvuttra. The stock plunged 29% as investors feared the flagship franchise's growth is decelerating, overshadowing strong Q2 results.
This is the single biggest new event of the period and the main reason ALNY is moving right now.
Amvuttra Tops $1 Billion in a Quarter for First Time Amvuttra exceeded $1 billion in quarterly sales, with total product revenue up 74% and non-GAAP operating income tripling to $318 million. This shows the drug is still growing strongly, but the guidance cut signals the pace will slow.
It is the key new financial result that contrasts with the guidance cut and explains the mixed market reaction.
Rival ATTR-CM Drug Fails, Boosting Alnylam's Competitive Edge AstraZeneca and Ionis's Wainua failed a Phase 3 ATTR-CM trial, removing a potential competitor. Alnylam shares initially rose 18% as its Amvuttra faces less competition in the cardiomyopathy market, though the later guidance cut reversed those gains.
This is a major new competitive development that initially drove the stock up and remains a positive force.
Securities Fraud Investigation Adds Legal Uncertainty Kirby McInerney launched an investigation into potential securities law violations following the guidance cut. While no lawsuit has been filed, the probe adds uncertainty and could pressure the stock as investors weigh legal risks.
It is a new negative development that could affect investor sentiment and is directly tied to the guidance cut.

July 20269 Jul – 31 Jul 2026

▲2▼2

Alnylam's TTR Guidance Cut Triggers 29% Plunge Despite Record Quarter

TTR Guidance Cut Sends Shares Down 29% Alnylam lowered its 2026 TTR revenue guidance to $4.2–4.5 billion from $4.4–4.7 billion, citing slower second-line demand for Amvuttra. The stock plunged 29% as investors feared the flagship franchise's growth is decelerating, overshadowing strong Q2 results.
This is the single biggest new event of the period and the main reason ALNY is moving right now.
Amvuttra Tops $1 Billion in a Quarter for First Time Amvuttra exceeded $1 billion in quarterly sales, with total product revenue up 74% and non-GAAP operating income tripling to $318 million. This shows the drug is still growing strongly, but the guidance cut signals the pace will slow.
It is the key new financial result that contrasts with the guidance cut and explains the mixed market reaction.
Rival ATTR-CM Drug Fails, Boosting Alnylam's Competitive Edge AstraZeneca and Ionis's Wainua failed a Phase 3 ATTR-CM trial, removing a potential competitor. Alnylam shares initially rose 18% as its Amvuttra faces less competition in the cardiomyopathy market, though the later guidance cut reversed those gains.
This is a major new competitive development that initially drove the stock up and remains a positive force.
Securities Fraud Investigation Adds Legal Uncertainty Kirby McInerney launched an investigation into potential securities law violations following the guidance cut. While no lawsuit has been filed, the probe adds uncertainty and could pressure the stock as investors weigh legal risks.
It is a new negative development that could affect investor sentiment and is directly tied to the guidance cut.

Latest9 Jul – 31 Jul 2026

▲2▼2

Alnylam's TTR Guidance Cut Triggers 29% Plunge Despite Record Quarter

TTR Guidance Cut Sends Shares Down 29% Alnylam lowered its 2026 TTR revenue guidance to $4.2–4.5 billion from $4.4–4.7 billion, citing slower second-line demand for Amvuttra. The stock plunged 29% as investors feared the flagship franchise's growth is decelerating, overshadowing strong Q2 results.
This is the single biggest new event of the period and the main reason ALNY is moving right now.
Amvuttra Tops $1 Billion in a Quarter for First Time Amvuttra exceeded $1 billion in quarterly sales, with total product revenue up 74% and non-GAAP operating income tripling to $318 million. This shows the drug is still growing strongly, but the guidance cut signals the pace will slow.
It is the key new financial result that contrasts with the guidance cut and explains the mixed market reaction.
Rival ATTR-CM Drug Fails, Boosting Alnylam's Competitive Edge AstraZeneca and Ionis's Wainua failed a Phase 3 ATTR-CM trial, removing a potential competitor. Alnylam shares initially rose 18% as its Amvuttra faces less competition in the cardiomyopathy market, though the later guidance cut reversed those gains.
This is a major new competitive development that initially drove the stock up and remains a positive force.
Securities Fraud Investigation Adds Legal Uncertainty Kirby McInerney launched an investigation into potential securities law violations following the guidance cut. While no lawsuit has been filed, the probe adds uncertainty and could pressure the stock as investors weigh legal risks.
It is a new negative development that could affect investor sentiment and is directly tied to the guidance cut.

Q2 202622 Jun – 3 Jul 2026

▲4

Alnylam's RNAi Engine Roars: AI Deals, Regulatory Wins, and a 121% Revenue Surge

Amvuttra's 187% sales jump powers 121% total revenue growth Amvuttra sales soared 187% to $889.9 million, driving total Q1 product revenue up 121% to $1.04 billion. This blockbuster growth is the core reason Alnylam's stock can rebound, as it proves the company's flagship drug is winning in the cardiomyopathy market.
This is the fundamental growth engine behind the stock's potential recovery and analyst optimism.
AI partnerships with Inceptive and Komodo aim to speed drug discovery and commercialization Alnylam formed a $2 billion AI collaboration with Inceptive Nucleics to accelerate RNAi drug discovery and expanded its Komodo Health partnership to scale AI analytics. These deals could shorten development timelines and boost pipeline productivity, supporting long-term growth.
These new AI initiatives signal future pipeline expansion and operational efficiency, key for a biotech's valuation.
Cemdisiran accepted for FDA and EMA review in myasthenia gravis Regulators accepted marketing applications for cemdisiran, with FDA priority review and a November decision date. This milestone brings a potential new rare-disease therapy closer to market, diversifying revenue beyond Amvuttra and adding a near-term catalyst.
A regulatory acceptance is a concrete step toward a new product approval, directly impacting future revenue.
Analysts see 45% upside as Brown Advisory initiates a position Wall Street's average price target is $436, about 45% above the recent close, and Brown Advisory initiated a stake citing an attractive entry point. These votes of confidence suggest the market may be undervaluing Alnylam's growth prospects.
Institutional buying and analyst targets reflect external validation of the company's value after a steep selloff.

June 202622 Jun – 3 Jul 2026

▲4

Alnylam's RNAi Engine Roars: AI Deals, Regulatory Wins, and a 121% Revenue Surge

Amvuttra's 187% sales jump powers 121% total revenue growth Amvuttra sales soared 187% to $889.9 million, driving total Q1 product revenue up 121% to $1.04 billion. This blockbuster growth is the core reason Alnylam's stock can rebound, as it proves the company's flagship drug is winning in the cardiomyopathy market.
This is the fundamental growth engine behind the stock's potential recovery and analyst optimism.
AI partnerships with Inceptive and Komodo aim to speed drug discovery and commercialization Alnylam formed a $2 billion AI collaboration with Inceptive Nucleics to accelerate RNAi drug discovery and expanded its Komodo Health partnership to scale AI analytics. These deals could shorten development timelines and boost pipeline productivity, supporting long-term growth.
These new AI initiatives signal future pipeline expansion and operational efficiency, key for a biotech's valuation.
Cemdisiran accepted for FDA and EMA review in myasthenia gravis Regulators accepted marketing applications for cemdisiran, with FDA priority review and a November decision date. This milestone brings a potential new rare-disease therapy closer to market, diversifying revenue beyond Amvuttra and adding a near-term catalyst.
A regulatory acceptance is a concrete step toward a new product approval, directly impacting future revenue.
Analysts see 45% upside as Brown Advisory initiates a position Wall Street's average price target is $436, about 45% above the recent close, and Brown Advisory initiated a stake citing an attractive entry point. These votes of confidence suggest the market may be undervaluing Alnylam's growth prospects.
Institutional buying and analyst targets reflect external validation of the company's value after a steep selloff.

22 Jun – 3 Jul 2026

▲4

Alnylam's RNAi Engine Roars: AI Deals, Regulatory Wins, and a 121% Revenue Surge

Amvuttra's 187% sales jump powers 121% total revenue growth Amvuttra sales soared 187% to $889.9 million, driving total Q1 product revenue up 121% to $1.04 billion. This blockbuster growth is the core reason Alnylam's stock can rebound, as it proves the company's flagship drug is winning in the cardiomyopathy market.
This is the fundamental growth engine behind the stock's potential recovery and analyst optimism.
AI partnerships with Inceptive and Komodo aim to speed drug discovery and commercialization Alnylam formed a $2 billion AI collaboration with Inceptive Nucleics to accelerate RNAi drug discovery and expanded its Komodo Health partnership to scale AI analytics. These deals could shorten development timelines and boost pipeline productivity, supporting long-term growth.
These new AI initiatives signal future pipeline expansion and operational efficiency, key for a biotech's valuation.
Cemdisiran accepted for FDA and EMA review in myasthenia gravis Regulators accepted marketing applications for cemdisiran, with FDA priority review and a November decision date. This milestone brings a potential new rare-disease therapy closer to market, diversifying revenue beyond Amvuttra and adding a near-term catalyst.
A regulatory acceptance is a concrete step toward a new product approval, directly impacting future revenue.
Analysts see 45% upside as Brown Advisory initiates a position Wall Street's average price target is $436, about 45% above the recent close, and Brown Advisory initiated a stake citing an attractive entry point. These votes of confidence suggest the market may be undervaluing Alnylam's growth prospects.
Institutional buying and analyst targets reflect external validation of the company's value after a steep selloff.